Active Ingredient(s): Burosumab
FDA Approved: * April 17, 2018
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Crysvita Overview

Burosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2][3] Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018.[4] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[4] This drug was developed by Ultragenyx and is in a collaborati...

Read more Crysvita Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Crysvita Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 10mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Crysvita: (3 results)

Sorted by National Drug Code
  • 69794-102 Crysvita 10 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
  • 69794-203 Crysvita 20 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
  • 69794-304 Crysvita 30 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.

Other drugs which contain Burosumab or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 May 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA